Physician profile

Jonathan K Bakos

Hematology & Oncology · Bluffton, SC

NPI 1609361278

$2,330.51

in general payments reported to CMS, 2019-2025

35 companies · $962 in 2025

The $962 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,131.52
Education$198.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $251.74 2024-2025 Keytruda, Lynparza, Keytruda Qlex
Janssen Biotech, INC. $246.72 2024-2025 Tecvayli, Darzalex, Rybrevant
Celgene Corporation $194.14 2024-2025 Reblozyl
Novocure INC. $185.11 2024-2025 Optune Lua (Novottf-200t)
Sobi, INC $167.56 2024-2025
Incyte Corporation $132.23 2024 Pemazyre, Monjuvi, Jakafi
E.R. Squibb & Sons, L.L.C. $108.03 2024-2025 Opdivo, Krazati
Regeneron Healthcare Solutions, INC. $100.82 2024-2025 Libtayo
Novartis Pharmaceuticals Corporation $74.89 2024-2025
Janssen Scientific Affairs, LLC $72.24 2023 Talvey, Tecvayli, Darzalex
Pfizer INC. $68.88 2024-2025
Boehringer Ingelheim Pharmaceuticals, INC. $51.79 2024-2025
Takeda Pharmaceuticals U.S.A., INC. $49.36 2024 Alunbrig
Array Biopharma INC $49.16 2024-2025 Lorbrena, Braftovi
Geron Corporation $45.11 2025 Rytelo
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Adc Therapeutics America, INC. $44.51 2025
Taiho Oncology, INC. $44.50 2024
Genzyme Corporation $37.40 2025
Astellas Pharma US INC $33.38 2025 Xtandi
Aveo Pharmaceuticals, INC. $31.71 2024
Lilly USA, LLC $29.74 2024 Jaypirca, Verzenio
Pharmacosmos Therapeutics INC. $29.21 2025 Monoferric
Blueprint Medicines Corporation $29.17 2024 Ayvakit
Bayer Healthcare Pharmaceuticals INC. $25.66 2025
Eisai INC. $24.29 2025
Astrazeneca Pharmaceuticals LP $24.18 2025 Imfinzi
Daiichi Sankyo INC. $23.68 2024 Enhertu
Kite Pharma, INC. $22.02 2025 Yescarta
Jazz Pharmaceuticals INC. $21.99 2025
Ipsen Biopharmaceuticals, INC $21.28 2025 Onivyde
Genentech USA, INC. $20.69 2024 Phesgo
Glaxosmithkline, LLC. $19.33 2024 Ojjaara
Stemline Therapeutics INC. $18.66 2025 Elzonris
Servier Pharmaceuticals LLC $16.60 2024
Tempus Ai, INC $14.73 2025 Xt Cdx

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan K Bakos

$2,330.51

in general payments reported 2019-2025

Years
2023-2025
Top company
Merck Sharp & Dohme LLC
Context
The $962 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/5566639/jonathan-k-bakos

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.